Combining MDS-UPDRS Parts 1 and 2: using the patient’s voice
Objective: To test whether the patient-derived MDS-UPDRS Parts assessing non-motor (Part 1) and motor (Part 2) functional impact of PD can be summed to render…Cervical percutaneous interferential current stimulation improves cough reflex and oral residue in patients with Parkinson’s disease
Objective: Patients with Parkinson's disease (PD) encounter various swallowing disorders. This study aimed to assess the effects of cervical percutaneous interferential current stimulation on pharyngeal…Opicapone as First-Line Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson’s Disease
Objective: This study aimed to explore the efficacy of opicapone (OPC) 50 mg versus an extra 100 mg levodopa (L-dopa) dose to treat early wearing-off…Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson’s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up
Objective: Evaluate long-term safety and efficacy of foslevodopa/foscarbidopa (LDp/CDp) among people with advanced Parkinson’s disease (aPD). Background: As aPD progresses, erratic gastric emptying and pulsatile…Effects of Mental Practice on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial
Objective: To compare the effects of an experimental intervention (EI) based on NCI with a control intervention (CI) of equal volume and intensity, differing only…Istradefylline effects on L-Dopa resistant tremor in Parkinson’s disease
Objective: Quantifying Istradefylline(IST) effects in L-Dopa(LD) resistant tremor in Parkinson’s disease(PD) patients. Background: The adenosine A2A receptors control the indirect pathway. Adenosine A2A receptor activation decreases…Incobotulinumtoxin A to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 5-year Interim Results
Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles (IC)). Background:…The effects of DL-3-n-butylphthalide in patients with mild cognitive impairment due to Parkinson’s disease: A multicenter, randomized, double-blind, placebo-controlled trial
Objective: To assess the therapeutic effect of DL-3-n-butylphthalide on cognitive impairment associated with Parkinson’s disease (PD). Background: PD associated cognitive impairment are attracting attention because…Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain
Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…An observational study of the efficacy, safety, and discontinuation rate of foslevodopa/foscarbidopa in 22 patients with advanced Parkinson’s disease
Objective: The aim of this observational study for PD patients treated with foslevodopa/foscarbidopa(LDP/CDP) is to evaluate clinical characteristics, therapeutic efficacy and safety, and to determine…
- « Previous Page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- …
- 436
- Next Page »